Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma

By          

Oncology Letters, Vol. 10, Iss. 2, 2015-01 ,pp. : 1171-1175

Spandidos Publications

Access to resources Recommend Favorite

Genetic polymorphisms of metabolic enzymes—CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility

By Luo Ya-ping  

Tumor Biology, Vol. 32, Iss. 1, 2011-02 ,pp. : 215-222

Springer Publishing Company

Access to resources Recommend Favorite

Study of the polymorphisms of cyclooxygenase2 (765G>C) and 5lipoxygenase (1708G>A) in patients with colorectal cancer

By              

Oncology Letters, Vol. 7, Iss. 2, 2014-01 ,pp. : 513-518

Spandidos Publications

Access to resources Recommend Favorite

CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity

By Burns K.   Goldthorpe M.   Porteus F.   Browett P.   Helsby N.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 651-655

Springer Publishing Company

Access to resources Recommend Favorite

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients

By Ferraldeschi Roberta  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1191-1198

Springer Publishing Company

Access to resources Recommend Favorite